See our Downloads ▼ section to access our document – providing an overview of all guidance currently available for medical technology innovation opportunities and adoption. It will be updated monthly, please check back frequently.
This document will include:
- Novel Innovation is available via the Dynamic Purchasing System (DPS).
- NHSE MedTech Funding Mandate opportunities.
- Value Based Procurement (VBP).
- Novel Innovation and new areas to frameworks.
The guide is built to be used by a variety of roles, for example, procurement professionals, clinical specialists, project improvement leads, finance managers and innovation leads.
It will help you to build work plans at a time suitable to you, highlighting different types of benefits that can be realised, and opportunities for improvement in some of the more challenging areas of your work.
We will continue to support you with this process but have made this information available here to be accessed as and when you need it.
Take our five-minute survey about this page
We need to hear from you about how you are using this page and how useful the information is. Please complete our short survey to give us your feedback.
Download the latest document
Key features:
- Products are broken down into speciality areas, and patients in scope.
- Product description.
- Hyperlinks to NICE guidance, cost savings and case studies.
- Links to NHS Supply Chain VBP and case studies.
- Reference site details.
- NPC codes.
- Financial benefits.
- Operational benefits.
- Patient benefits.
- Environmental benefits.
- Key stakeholders.
- Health Innovation Network (HIN) Lead if MedTech Funding Mandate (MTFM).
- Additional resources.
- Contact details (in addition to your Hospital Care Team – ICS Managers).
New updates in June 2025
See our Downloads ▼ section to access the full document detailing all of our value-driving opportunities. Each month, we’ll provide a high-level summary of the latest updates.
Latest DPS: Tensi+
Product Description: Tensi+ is a non-pharmacological and non-invasive medical device for managing overactive bladder symptoms stemming from either idiopathic or neurological causes. It does not involve the use of medication or surgical interventions, thereby avoiding potential side effects associated with such treatments. Overactive bladder (OAB) is a chronic condition without a definitive cure. However, Tensi+ provides an option to effectively manage and help alleviate the symptoms of this condition through a different therapeutic approach.
| Areas of implementation and adoption | NHS Priorities | How does this improve the patient’s pathway? | Potential sustainability benefits |
| Acute Care Chronic Disease Management General Surgery Outpatient Clinics. | Prevention and Health Inequalities Use of Resources. | Improved Patient Experiences Improved Patient Outcomes Reduce Health Care Inequality Patient Empowerment Pain Reduction. | Reduction in product usage Reduction in patient and visitor travel Reduction in waste. |
Latest DPS: AMBLor ®
Product Description: Dual antibody IHC prognostic test for identifying which early-stage non-ulcerated melanomas (Stages IA-IIB) are at low risk of metastasis
| Areas of implementation and adoption | NHS Priorities | How does this improve the patient’s pathway? | Potential sustainability benefits |
| Advanced Diagnostics Cancer Screening Dermatology Oncology Plastic Surgery. | Early Diagnosis and Treatment of Cancer Addressing Health Inequalities Reducing Elective Care Backlogs Use of resources. | Decreased Waiting Lists Reduce health care inequality Decreased appointment time Improved Patient Experiences Patient Empowerment. | Reduction in medicines/pharmaceuticals Reduction in patient and visitor travel Reduction in Chemicals. |
DPS Customer Queries
Latest VBP : BLISTER Score Risk stratification tool
Real-time pacemaker data transmission, enhancing patient management and reducing clinic visits.
| Areas of implementation and adoption | NHS Priorities | How does this improve the patient’s pathway? | Potential sustainability benefits |
Cardiology | – | Reduction in infection Faster Recovery Times Improved Patient Outcomes Reduced Infection Rates Improved Patient Experiences Increased Safety Better Pre-Operative Health | Reduction in medical gases. Reduction in medicines/pharmaceuticals Reduction in product usage. |
See our Useful Links section for details of your regional Care Pathway Team, who can conduct trust-specific financial modelling on this value-driving opportunity.
Latest Sustainability : Pee in Pot
Developed within a trust, this opportunity is a Class 1 IVD (Urine Collection Vessel)- manufactured from a blend of white sugar cane pulp (Bagesse)/bamboo fibre (aka – as Thermofibre) UKCA. A sustainable alternative to current processes and products used in a mid-stream urine (MSU) collection process
| Areas of implementation and adoption | NHS Priorities | How does this improve the patient’s pathway? | Potential sustainability benefits |
| Acute Care Community Sexual and Reproductive Health Maternity. | Diagnostics Use of resources. | Improved Staff Experiences. | Reduction in CO2 emissions Reduction in packaging Reduction in product usage Reduction in waste. |
For further details on this value-driving opportunity, please contact us.
Sustainability Team
Latest MTFM : Apos Health
A non-invasive device for knee pain, improving mobility and deferring surgery with personalised treatment.
| Areas of implementation and adoption | NHS Priorities | How does this improve the patient’s pathway? | Potential sustainability benefits |
| Orthopaedics | Reducing elective care backlogs | Better pre-operative health Cashable savings Cost avoidance Decreased waiting lists | Reduction in CO2 emissions Reduction in patient and visitor travel |
See our Useful Links section for details of your regional Care Pathway Team, who can conduct trust-specific financial modelling on this value-driving opportunity.